Adverse reactions to human plasma proteins range from mild urticaria to fatal anaphylaxis and may occur with virtually any blood product. The most common clinical settings appear to be whole blood transfusion in subjects with no previous history of reactions, or the infusion of fresh frozen plasma or injection of human immune serum globulin (H/SG) to patients with known immunodeficiency. The immunological processes involved and the management of reactions are discussed.
INTRODUCTION
Adverse reactions to plasma may occur in a variety of clinical situations and their severity may range from mild urticaria to fatal systemic anaphylaxis. It is possible that an allergic IgEmediated reaction may occur in a sensitized individual receiving a blood or plasma infusion containing the agent to which he is allergic, for example a drug. Adverse reactions to plasma in the present context denote reactions to plasma proteins.
Albumin is the major plasma protein but reactions to it are rare. A recent report discussed a series of patients who developed anaphylactoid reactions after multiple infusions of pasteurized plasma (PP), stable plasma protein solution (SPPS), or human serum albumin. I These preparations are primarily used as plasma expanders and this group is discussed in another paper in this symposium issue. 43 This paper will only refer to reactions to 'M.D., B.S., F.R.A.C.P., F.R.C.P.A., F.A.C.P., Senior Staff Specialist in Clinical Immunology. *"'B.Se .• Scientific Officer. human plasma proteins, although similar immunological processes are involved in the reactions which occur after treatment with antisera or antivenenes from immunized animals; for example, diphtheria anti-toxin prepared in horses or, more rarely, antilymphocyte globulin prepared in sheep.
Adverse reactions have been noted with virtually any blood product which includes plasma proteins, e.g. whole blood, packed red cells, plasma, human immune serum globulin (HISG), and Factor VIII cryoprecipitate. The most important ones however have been transfusion of whole blood, infusion of fresh frozen plasma, and injection of HISG.
BLOOD PRODUCTS AND PLASMA PROTEINS Allotypes are genetically determined antigenic differences in different members of the same species. While antigenic differences on blood elements and antibodies to these antigens form the raison d'ftre for blood banks, it should also be remembered that allotypic markers occur on plasma proteins. The administration of blood that has been correctly typed and crossmatched by conventional methods may still produce sensitization to different allotypic markers on some plasma proteins, but for the great majority of cases these differences do not appear biologically significant, any antibodies produced are in low titre, and they are not associated with clinically significant adverse reactions. The most polymorphic plasma proteins are the major serum immunoglobulins IgG, IgA and IgM, and these are the basis of most clinically significant reactions involving plasma proteins. SUBJECTS Subjects with selective IgA deficiency may develop many autoantibodies and isoantibodies including antibodies to bovine IgM, bovine milk, goat serum, thyroglobulin, collagen and various tissue antigens. 6 ,7 Of greater interest to the present discussion is their tenden'cy to develop antibodies to human immunoglobulins. Antibodies to human IgG and human IgM have been reported. s IgG class anti-IgG antibodies were found in low titre in 8070 of subjects with selective IgA deficiency and had no association with clinical features nor blood transfusion reactions. IgM-class and IgG-class isoantibodies to human IgM were found in titres ranging from 1 in 4, to 1 in 1,024 in 35070 of subjects with selective IgA deficiency compared to low titres of limited specificity in 1.6070 of normal blood donors 9 and 7070 of subjects receiving multiple blood transfusions. However, no role has ever been established for anti-IgM antibodies in the production of adverse reactions to blood transfusion.
The most important feature of these subjects with selective IgA deficiency however is their tendency to develop antibodies to human IgA and the role of these antibodies in adverse reactions is discussed below.
Patients with major defects in B-cell function, e.g. common variable hypogammaglobulinaemia, often show significant symptoms from recurrent infections and may be treated with plasma infusions or regular injections of HIS(J2·IO to compensate for their immunoglobulin deficiency. It is a surprising paradox that such patients with a major defect in their antibody-producing capacity may yet retain the ability to develop IgG-class anti-IgA antibodies and undergo severe anaphylactic reactions. [11] [12] [13] Occasionally, it is the IgG in HISG which is responsible for the adverse reaction and these mechanisms are discussed below.
Patients with normal immunoglobulin levels may develop antibodies to specific allotypic determinants on IgG molecules -the Gm markers -as a result of multiple blood transfusions. 14 However, adverse reactions from these antibodies are rare.
PATHOPHYSIOLOGY OF REACTIONS

Anti-IgA antibodies
These IgG-class antibodies have been recognised since 1968. 15 Their prevalence varies from 20-60070 of subjects with selective IgA deficiency, compared to values of 1-2070 of normal subjects in most series. 16 -20 In most cases these subjects have not been previously transfused. An interesting study in French blood donors found a high prevalence (59070) of anti-IgA antibodies in normal blood donors and this was not significantly different from their prevalence in patients with anaphylactic transfusion reactions. 21 However the majority of those normal sera contained antibodies of very low titre (1/2 to 1/8) and were of limited specificity. The prevalence in Australian subjects with selective IgA deficiency was 27CTJo in normal blood donors but 60CTJo in patients who presented with autoimmune disease or recurrent infection. Anti-IgA antibodies are detected by haemagglutination techniques with a panel of 0 Rh(D) POS red cells coated with a panel of IgA myeloma proteins and normal IgA. 22 Other methods such as polymer-induced precipitation in agarose geF3 have not gained wide acceptance. The haemagglutinationinhibition studies have revealed a wide range of specificities of anti-IgA antibodies ( Class-specific: Antibodies react with all IgA proteins 2.
Subclass-specific: Anti-lgAI or anti-IgA2 3.
Anti-allotypic: anti-A2m(l) 4.
Anti-isoallotypic: anti-nA2m(2) 5.
Limited: Antibodies with activity against only one or a few of the IgA proteins may represent one of the following -(a) a combination of 2, 3, 4 above (b) discovery of a new allotype (c) "idiotypic" specificity with reactivity solely against one IgA myeloma protein
In general, the risk of serious adverse reactions is associated with subjects who have high titre (1 in 256 or greater) class-specific anti-IgA antibodies who receive blood products containing IgA. "Class-specific" means the antibodies react with all IgA molecules. The antibodies are complement-fixing and serum complement levels may fall following this interaction between IgA and anti_IgA. 22 . 26 Experiments with radiolabelled IgA show the injected IgA is cleared from the recipient's blood very rapidly. 27, 28 The clinical features of the reaction are thought to result from the release of complement fragments which have a direct action, e.g. kinin-like activity in C3a or C4a2b, or which release vasoactive amines (including histamine) from basophils and/or mast cells, e.g. C3a and C5a. 29 The biological activities of these complement fragments are normally controlled by the action of a plasma enzyme "anaphylatoxin inactivator", an a-protein of molecular weight 300,000, with carboxypeptidase B-like activity which rapidly destroys C3a and to a lesser extent C5a. 29 However, a study of anaphylactoid reactions to radiographic contrast media 30 found normal levels of anaphylatoxin inactivator. The factors which control the balance between complement fragments, enzyme levels and activities, and target cell damage leading to anaphylaxis, are unknown. Thus one may see the features of systemic anaphylaxis: apprehension; chest, abdominal or lumbar pain; hypotension, marked flushing of face and neck; dyspnoea; cyanosis and wheezing. Occasionally one may see diarrhoea, vomiting, chills and fever, and loss of consciousness.
Anti-IgA antibodies of limited specificity, especially in low titre, tend to be associated with a significantly milder clinical spectrum with urticarial or erythematous skin rashes and occasional mild anaphylactoid symptoms. It is not known if the pathogenetic mechanisms are different from those with class-specific anti-IgA antibodies. Despite the general rule, serious, even fatal, reactions may occur with anti-IgA of limited specificity.22.31 The antigenantibody reaction is very sensitive so that adverse reactions may occur from transfusion of only a few millilitres of blood containing only a few milligrams of IgA. Because of this sensitivity, reactions due to anti-IgA antibodies may occur after the intramuscular or intravenous injection of HISG preparations since they contain small amounts of IgA. A study of 40 such preparations found IgA in all preparations, at concentrations of 0.1-26.5 mg/ml, out of an average total protein concentration of 160 mg/m1. 32 The IgA occurred as aggregates, monomers and IgA fragments.
Rarely, anti-IgA antibodies of limited specificity (anti-allotypes) may develop in patients with normal serum IgA levels after multiple blood transfusions, but they tend to produce mild reactions.
Anti-JgG antibodies
The rare reactions due to Gm markers on IgG molecules in transfused blood reacting with 1. V. WELLS AND M. A. KING anti-Gm antibodies in the recipient appear to result from a similar mechanism to that postulated for anti-IgA antibodies.
Reactions may occur in some patients after prolonged treatment with HISG, and clinically they vary from mild to fatal. In some cases, anti-IgG antibodies can be demonstrated. One report demonstrated antibodies to an antigenic determinant present only on aggregated IgGY
Immunoglobulin aggregates
Antibodies to immunoglobulin molecules cannot be demonstrated in many patients who react to HISG and it is thought that the reactions in such cases are due to direct activation of the complement system by immunoglobulin aggregates in the HISG. 34 These aggregates develop in the HISG during storage, even at 4 DC. 35 It is the anticomplementary activity of these aggregates and their potential to cause anaphylactic reactions which prompted the rule that intramuscular HISG must never be given intravenously.
Attempts were made to· modify the IgO molecules by enzymatic or other means so that aggregates did not form and the HISG was suitable for intravenous administration. 36.37 Unfortunately, the procedures which affect the Fc part of the IgG molecules to prevent aggregate formation thereby also affect the metabolism of the molecules so that a significant fraction of the preparation is rapidly cleared from the body.38
MANAGEMENT OF REACTIONS
Such a reaction usually occurs as an unexpected but potentially life-threatening event and initial management is always directed at stabilisation of the patient according to routine principles of intensive care medicine. The clinical severity will determine whether drugs will be systematically administered, e.g. adrenaline, antihistamine or corticosteroid.
It is a cardinal rule in severe adverse reactions that the putative offending agent be stopped immediately. This is a relatively simple decision where a patient in a ward has recently started receiving a blood transfusion or plasma infusion, or HISG has been injected. It is more difficult in the operating theatre where there is also the possibility of anaphylaxis to anaesthetics,39 muscle relaxants 4o • 41 and radiographic contrast media. 42 For investigation, pre-and post-transfusion samples of the recipient's blood are required, as well as the transfused blood. Routine studies of blood groups and antibodies, and white cell antibodies would be performed as recommended for all blood transfusion reactions. Some of the tests to confirm an adverse reaction to plasma proteins are listed in Table 3 . If such studies show the patient has selective IgA deficiency and anti-IgA antibodies, and no other cause for the reaction is found, then one is justified in assuming that is the likely cause. One is not justified in injecting a small test amount of IgA to confirm the diagnosis because of the risk of a further reaction and stimulation of a higher antibody titre. Measurement of serum levels of C3, C4 and CHso in recipient before and after the transfusion 3.
Detection of C3 split products 4.
Detection of anti-immunoglobulin antibodies (especially anti-IgA) by haemagglutination 5.
Characterisation of any antibodies by titre and specificity Prophylaxis of such adverse reactions involves prevention of sensitisation and avoidance of exposure. The problem with preventing sensitisation of patients with selective IgA deficiency and the development of anti-IgA antibodies is that one cannot identify the cause in the majority of cases. Postulated mechanisms include previous transfusion or injection of blood products, immunisation by fetal or maternal blood during pregnancy or at delivery, or by cross-reaction with animal IgA proteins through the gastrointestinal tract. 22 Therefore patients known to have selective IgA deficiency should not be transfused with blood containing IgA. There are three means available to administer blood with no IgA to such patients. 1. Storage of autologous blood for subsequent administration. 2. Administration of red cells after freezing since the washing and deglycerolisation removes residual IgA. 3. Establishment of Rare Donor Files in blood banks with panels of donors with selective IgA deficiency. This was first done in the U .S.A. and then in several countries including U.K., Canada, Denmark, Finland and Australia.
